| miR-17 92(miRNA-17,miRNA-18a,miRNA-19a,miRNA-19b,miRNA-20a,and miRNA-92) | Normal tissue samples vspatients and (Saos2, U2OS vsNormal cells | 3 UTR of cMYC contained bindingsites for any of the 14q32-associatedmiRNAs and miR-17-92 andinduced c-MYC regulation. | 13,14q32(C13Orf25) | cMYC | FACS, Bluefuse microarraysoftware, Cell invasion andmigration assay, Arraycomparative genomehybridization, Osteoblastdifferentiation assay, Westernblot. Luciferase reporterassays, qRT-PCR,Nucleofection of miRNAmimics | Thayanithy et al.(2012);Shimada,(2013) |
| miR-33a | OS patients samples, Saos-2 ,MG-63 vs normal tissue, celllines | miR-33a is up regulated inchemoresistant OS which inhibitsthe TWIST-3 untranslated regionluciferasereporter activity and alterthe TWIST expression | 22 | TWIST | miRNA microarray analysis,qRT-PCR, Western blotanalysis, Luciferase assay,Measurement of apoptosis byTUNEL assay | Zhou et al. (2014) |
| miR-362 | Gastric cancer tissues and celllines vs normal tissue and celllines | Induced nuclear translocation of p65and inversely regulate the CYLDexpression by binding its 3untranslated region. | Xp11.23 | CYLD andp65 | Colony assay, flow cytometry,TUNEL assay, luciferasereporter assay, fluorescentimmunostaining, Westernblotting and qRT-PCR | Xia et al. (2014) |
| MiR-125a andmiR-125b | HCT116, OS and Humankeratinocyte cell lines vsHEK293 cell lines | MicroRNA-125b Up-regulationPromotes Cell Survival byTargeting p38α | 14q32 | p38α,TNFAIP3,and A20 | Immunoblotting, LuciferaseAssay, EMSA, ChIP and CellSurvival Assay | Kim et al. (2012);Tan et al. (2012) |
| miR-150, miR-199b-5p,miR-451 and solexa-578-1915 | ES97, HS3.T, SJSA-1, andMG63 and patients tissuesamples vs normal cells | miRNAs inhibitor showed a changein expression of Notch downstreamtargets | 9 | Notch1, Dll1,JAG1, HES1,Dtx1 | qRT-PCR, microarrayanalysis | Won et al. (2013) |